Multicenter, open-label, single dose study to evaluate safety, tolerability and pharmacokinetics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate
|Effective start/end date||1/1/16 → 9/30/21|
- NOVARTIS PHARMACEUTICALS CORPORATION
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.